NK

Neeraj Kumar

Active Director Director DIN 09700294
DIN 09700294 First appointment Aug 2022 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2022
Shareholding value •••• Premium profile

About Neeraj Kumar

Data last updated:

Neeraj Kumar is a Director at Rejuvenaids Private Limited (since 2022). The company operates in Healthcare. Rejuvenaids Private Limited reported revenue of ₹52.2 Lakh (FY 2025).

DIN 09700294
Primary Designation Director
Industry Healthcare
First Appointment 10 Aug 2022
Oldest Company Age 4 yrs
Largest company Rejuvenaids Private Limited · ₹52.2 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Rejuvenaids Private Limited U85110DL2022PTC402986
Director10 Aug 20222022₹52.2 Lakh (FY 2025)Active

Board colleagues of Neeraj Kumar

NameDINCompanyDesignation
Astuty Apurwa09700295Rejuvenaids Private LimitedDirector

Directorship timeline

Open interactive timeline →
Rejuvenaids Private Limited
Premium access

Shareholding and investment profile for Neeraj Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Neeraj Kumar

Neeraj Kumar currently holds 1 directorship: Rejuvenaids Private Limited (Director, since 10 Aug 2022, revenue ₹52.2 Lakh (FY 2025)).

Neeraj Kumar was first appointed on 10 Aug 2022 as Director at Rejuvenaids Private Limited.

The current boards of Neeraj Kumar's companies include Astuty Apurwa (Rejuvenaids Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available